Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863923 | 0.77 | ACHE (0.44) | HTR2A | |
| SCHEMBL24386022 | 0.77 | HTR2A (0.32) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL26678187 | 0.77 | HTR2A (0.32) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL275458 | 0.77 | HTR2A (0.45) | SIGMAR1HTR2AKDM1A | |
| SCHEMBL16870529 | 0.77 | GRIN2D (0.45) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL30968744 | 0.77 | — | — | |
| SCHEMBL12228571 | 0.77 | — | — | |
| SCHEMBL19322242 | 0.77 | PRCP (0.38) | SIGMAR1HTR2A | |
| SCHEMBL23555011 | 0.73 | IDO1 (0.33) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL23879407 | 0.73 | IDO1 (0.47) | SIGMAR1HTR2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | SYNAFFIX B.V. (NL) | 2023-11-16 | — | — | US | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2023-09-28 | — | — | US | disclosed |
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-09-28 | — | — | US | disclosed |
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-09-28 | — | — | US | disclosed |
| US-20230293719-A1 | PEPTIDE-LIPOSOME COMPLEX FOR MULTIVALENT CROSSLINKING WITH PD-L1 AND COMPOSITION INCLUDING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| US-20230250248-A1 | CATALYST-FREE SURFACE FUNCTIONALIZATION AND POLYMER GRAFTING | ILLUMINA, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | SYNAFFIX B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| WO-2011100131-A9 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110256227-A1 | CONTROLLED POLYPLEX ASSEMBLY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011113065-A2 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224383-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224383-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011100131-A2 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACUTICALS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100210854-A1 | Cyclopropenones and the Photochemical Generation of Cyclic Alkynes Therefrom | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2009067663-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | GRIN1 574/4885GRIN2B 1885/4885SIGMAR1 2410/4885 |
| US-20230293719-A1 | PEPTIDE-LIPOSOME COMPLEX FOR MULTIVALENT CROSSLINKING WITH PD-L1 AND COMPOSITION INCLUDING THE SAME | PDCD1LG2, CD274, PDCD1 | GRIN1 3198/4885GRIN2B 4158/4885SIGMAR1 4368/4885 |
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | CTSV, ACE2, CTSL | GRIN1 2637/4885GRIN2B 2734/4885SIGMAR1 4024/4885 |
| US-20110256227-A1 | CONTROLLED POLYPLEX ASSEMBLY | PARG, PARN, PUF60 | GRIN1 4618/4885GRIN2B 4509/4885SIGMAR1 4130/4885 |
| US-20230302038-A1 | RNAS FOR COMPLEMENT INHIBITION | SNRPE, RNASE1, SNRPF | GRIN1 4519/4885GRIN2B 4094/4885SIGMAR1 4016/4885 |
| US-20230364262-A1 | VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES | FCGR1A, FCGR3B, FCGR2A | GRIN1 1932/4885GRIN2B 2754/4885SIGMAR1 2818/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | GRIN1 4873/4885GRIN2B 4860/4885SIGMAR1 3281/4885 |
| US-20100210854-A1 | Cyclopropenones and the Photochemical Generation of Cyclic Alkynes Therefrom | WEE1, WEE2, MPI | GRIN1 3208/4885GRIN2B 3526/4885SIGMAR1 3101/4885 |
| US-20230127659-A1 | ANTIBODY-CONJUGATES WITH IMPROVED THERAPEUTIC INDEX FOR TARGETING HER2 TUMOURS AND METHOD FOR IMPROVING THERAPEUTIC INDEX OF ANTIBODY-CONJUGATES | FUT6, FUT5, FUT4 | GRIN1 1340/4885GRIN2B 2533/4885SIGMAR1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.